Ryvu presents RVU602 data: what it means for Ryvu Therapeutics stock

Published on 10/18/2026 at 12:31 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

Ryvu reported 100 percent remissions in a mouse model on October 14, 2026. Ryvu Therapeutics stock was last at PLN 18.04 on October 16, 2026.

RVU602 data and company figures

Ryvu presented RVU602 results on October 14, 2026, including complete responses in 100 percent of animals.
Revenue reached PLN 28.939 million in the first half of 2026, while net income was negative PLN 25.705 million.
The company's market capitalization stood at PLN 417.1 million on October 16, 2026.

Ryvu Therapeutics, PLSELVT00013, Illustration mit AI erstellt.

Ryvu Therapeutics (ISIN PLSELVT00013) reported complete responses in 100 percent of animals in a preclinical RVU602 study on October 14, 2026. The results add a quantified development milestone to the clinical-stage biotechnology company's oncology pipeline, while the stock's latest GPW quotation dates from October 16, 2026.

Three dated Ryvu milestones

On September 18, 2026, Ryvu concluded a grant agreement for the PANACEA-NOVO project with recommended funding of PLN 105.624 million and a total project value of PLN 133.187 million, according to Investing.com. The first half of 2026 produced revenue of PLN 28.939 million, EBITDA of negative PLN 24.702 million and net income of negative PLN 25.705 million, according to Stockd. On October 14, 2026, Ryvu presented RVU602 data at the World ADC Congress, as reported in the company's regulatory communication carried by PB.

What does RVU602 mean for investors?

The data are notable because the sacituzumab-RVU602 antibody-drug conjugate produced complete responses in 100 percent of animals after two weekly doses of 10 milligrams per kilogram in a TROP2-positive tumor model. Four doses of 5 milligrams per kilogram produced complete responses in 83 percent of animals. The study also tested four antibody partners and showed 100 percent efficacy with low-nanomolar activity in patient-derived TROP2-positive cells.

Revenue remains an important counterweight

The development data sit beside a smaller operating base. First-half 2026 revenue of PLN 28.939 million was accompanied by a net loss of PLN 25.705 million, while EBITDA was negative PLN 24.702 million. That combination leaves clinical validation and external funding as central variables in the investment case. Ryvu's business is focused on small-molecule oncology treatments, including the RVU120 program and antibody-drug conjugate research.

Stock and valuation context

Ryvu is listed on the Warsaw Stock Exchange under ticker RVU.WA. The last GPW quote was PLN 18.04 on October 16, 2026 at 5:01 p.m. CEST. Market capitalization stood at PLN 417.1 million on that date, and the 52-week range was PLN 13.64 to PLN 31.90.

Pipeline evidence shapes the next phase

For investors, the immediate value of the RVU602 update is scientific rather than commercial: the results are preclinical and do not establish clinical efficacy. The combination of complete responses in the HCC70 model, activity across four antibody targets and first-half net income of negative PLN 25.705 million frames both the opportunity and the funding risk.

The further course of trading is shown by the continuously updated real-time quote of Ryvu Therapeutics stock.